Compare BBWI & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBWI | ADPT |
|---|---|---|
| Founded | 1963 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.5B |
| IPO Year | 1994 | 2019 |
| Metric | BBWI | ADPT |
|---|---|---|
| Price | $21.40 | $29.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | $24.93 | ★ $32.57 |
| AVG Volume (30 Days) | ★ 6.0M | 2.0M |
| Earning Date | 11-19-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 1.49 | N/A |
| Revenue | ★ $7,291,000,000.00 | $276,976,000.00 |
| Revenue This Year | N/A | $10.85 |
| Revenue Next Year | $1.69 | $21.60 |
| P/E Ratio | $14.18 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $14.28 | $12.00 |
| 52 Week High | $24.94 | $32.21 |
| Indicator | BBWI | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 58.55 |
| Support Level | $17.60 | $24.02 |
| Resistance Level | $23.86 | $29.92 |
| Average True Range (ATR) | 0.82 | 1.83 |
| MACD | -0.25 | 0.35 |
| Stochastic Oscillator | 11.69 | 60.05 |
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 4% of sales from international markets in fiscal 2025. For fiscal 2025, 77% of sales stemmed from the brick-and-mortar network of more than 1,900 retail stores, similar to 2024 levels, as consumer shopping patterns remained normal. Future growth is expected from store upgrades, digital and international channels, as well as adjacent category expansions like lip.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.